Partnering Deals and Alliances with Big Biotech

NEW YORK, Oct. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Partnering Deals and Alliances with Big Biotech

http://www.reportlinker.com/p01590713/Partnering-Deals-and-Alliances-with-Big-Biotech.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

Partnering Deals and Alliances with Big Biotech provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companiesOver 300 charts showing a company's dealmaking activity since 2007, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2007 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

The Partnering Deals and Alliances with Big Biotech report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big biotech companies.

This premier report provides all the information you require to better understand big biotech partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of each big biotech companies dealmaking trends over the last four years.

This report contains over 1,500 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by big biotech and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of big biotech's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading big biotech companies based on 2012 pharmaceutical revenues and dealmaking activity since 2007.

Chapter 3 reviews the top partnering and M&A deals of 2007-2013 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to big biotech, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with big biotech provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of every big biotech company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.

Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 1,500 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right big biotech partners effectively and efficiently.

Key benefits

Partnering Deals and Alliances with Big Biotech provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big biotech companies

Over 300 charts showing a company's dealmaking activity since 2007, allowing quick identification potential partners

Partnering therapy focus revealed

Partnering activity since 2007 – number of deals per year

Full listing of partnering deals

Activity by deal type

Activity by industry sector

Activity by phase of development

Activity by technology type

Activity by therapeutic area

Comprehensive access to over 1,500 partnering deals as recorded at Current Agreement, together with contract documents if available

Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents

Understand the key deal terms the company has agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Deals and Alliances with Big Biotech is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big biotech companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's partnering.

Partnering Deals and Alliances with Big Biotech includes:

Detailed company profiles for each of the top 50 big biotech companies, including:

Partnering interests and indications

Partnering activity since 2007

Partner companies since 2007

Partnering activity since 2007 by:

Partner company

Deal type

Industry sector

Stage of development

Technology type

Therapy area

Over 300 charts showing the dealmaking activity of each company since 2007

The tools to enable effective and efficient preparation for partnering negotiation with big biotech

1,500 partnering deals as recorded at Current Agreement, together with contract documents if available

The leading M&A and partnering deals by value 2007-2013

The Partnering Deals and Alliances with Big Biotech report also provides comprehensive access to available contract documents for each of the fifty big biotech companies.

Analyzing actual company agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How are sales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subscontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:

Detailed partnering activity profiles for each of the top 50 big pharma companiesOver 300 charts showing a company's dealmaking activity since 2007, allowing quick identification potential partnersPartnering therapy focus revealedPartnering activity since 2007 – number of deals per yearFull listing of partnering dealsActivity by deal typeActivity by industry sectorActivity by phase of developmentActivity by technology typeActivity by therapeutic areaComprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if availableInsight into the terms included in a partnering agreement, together with real world clause examples, via contract documentsUnderstand the key deal terms the company has agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Big biotech top 50 dealmaking activity

2.1. Introduction 2.2. Big biotech partnering over the years 2.4. Big biotech partnering by deal type 2.6. Big biotech partnering by stage of development2.7. Big biotech partnering by technology type2.8. Big biotech partnering by therapy area2.9. Big biotech M&A over the years

Chapter 3 – Top big biotech deals by value

3.1. Introduction

3.2. Big bioteh partnering

3.3. Big biotech M&A

Chapter 4 – Submitting opportunities to big biotech

4.1. How to submit an opportunity4.2. Opportunity submission template4.3. Sending emails4.4. Face to face at partnering events4.5. Online submission forms

Chapter 5 – Forthcoming big biotech partnering events

5.1. Forthcoming events

Chapter 6 – Big biotech company profiles

6.1. Introduction 6.2. Field definitions 6.3. Company profiles 3SBio Acorda TherapeuticsActelionAlexion PharmaceuticalsAlkermesAlnylam PharmaceuticalsAMAG PharmaceuticalsAmgenAnika TherapeuticsArray Biopharma Bavarian Nordic BioconBiogen IdecBioMarin PharmaceuticalsCangeneCelgeneCSLCubistDendreonElanEmergent BioSolutionsEnzo BiochemGalapagosGenmabGilead SciencesGrifols Ipsen Isis PharmaceuticalsLFB Group MedivationMorphosysNektar TherapeuticsNovo NordiskNPS PharmaceuticalsOnyx PharmaceuticalsOptimer PDL BioPharmaQuestcor PharmaceuticalsRegeneron PharmaceuticalsRocheSciClone PharmaceuticalsSeattle GeneticsShireSpectrum PharmaceuticalsSwedish Orphan BiovitrumThe Medicines CompanyUCBUnited TherapeuticsVertex PharmaceuticalsViroPharmaZeltia

Chapter 7 – Resources

Appendices

Appendix 1 – Deal type definitions

Appendix 2 – Example contract document

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

TABLE OF FIGURES

Figure 1: Big biotech partnering 2007-2013

Figure 2: Big biotech – top 50 partnering activity 2007 to 2013

Figure 3: Big biotech deal frequency – 2007 to 2013

Figure 4: Big biotech partnering by deal type 2007-2013

Figure 5: Big biotech partnering by stage of development 2007-2013

Figure 6: Big biotech partnering by technology type 2007-2013

Figure 7: Big biotech partnering by therapy area 2007-2013

Figure 8: Big biotech M&A 2007-2013

Figure 9: Big biotech – top 50 M&A activity 2005-2013

Figure 10: Big biotech M&A deal frequency 2007-2013

Figure 11: Leading partnering deals by value, 2007-2013

Figure 12: Leading M&A deals involving big biotech by value, 2007-2013

Figure 13: Typical partnering opportunity submission template

Figure 14: Company profile template and definitions used in report

Figure 15: 3SBio: Dealmaking frequency 2007-2013

Figure 16: 3SBio: Partnering deals by type

Figure 17: 3SBio: Partnering deals by industry sector

Figure 18: 3SBio: Partnering deals by technology type

Figure 19: 3SBio: Partnering deals by stage of development

Figure 20: 3SBio: Partnering deals by therapy area

Figure 21: Acorda Therapeutics: Dealmaking frequency 2007-2013

Figure 22: Acorda Therapeutics: Partnering deals by type

Figure 23: Acorda Therapeutics: Partnering deals by industry sector

Figure 24: Acorda Therapeutics: Partnering deals by technology type

Figure 25: Acorda Therapeutics: Partnering deals by stage of development

Figure 26: Acorda Therapeutics: Partnering deals by therapy area

Figure 27: Actelion: Dealmaking frequency 2007-2013

Figure 28: Actelion: Partnering deals by type

Figure 29: Actelion: Partnering deals by industry sector

Figure 30: Actelion: Partnering deals by technology type

Figure 31: Actelion: Partnering deals by stage of development

Figure 32: Actelion: Partnering deals by therapy area

Figure 33: Alexion Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 34: Alexion Pharmaceuticals: Partnering deals by type

Figure 35: Alexion Pharmaceuticals: Partnering deals by industry sector

Figure 36: Alexion Pharmaceuticals: Partnering deals by technology type

Figure 37: Alexion Pharmaceuticals: Partnering deals by stage of development

Figure 38: Alexion Pharmaceuticals: Partnering deals by therapy area

Figure 39: Alkermes: Dealmaking frequency 2007-2013

Figure 40: Alkermes: Partnering deals by type

Figure 41: Alkermes: Partnering deals by industry sector

Figure 42: Alkermes: Partnering deals by technology type

Figure 43: Alkermes: Partnering deals by stage of development

Figure 44: Alkermes: Partnering deals by therapy area

Figure 45: Alnylam Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 46: Alnylam Pharmaceuticals: Partnering deals by type

Figure 47: Alnylam Pharmaceuticals: Partnering deals by industry sector

Figure 48: Alnylam Pharmaceuticals: Partnering deals by technology type

Figure 49: Alnylam Pharmaceuticals: Partnering deals by stage of development

Figure 50: Alnylam Pharmaceuticals: Partnering deals by therapy area

Figure 51: AMAG Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 52: AMAG Pharmaceuticals: Partnering deals by type

Figure 53: AMAG Pharmaceuticals: Partnering deals by industry sector

Figure 54: AMAG Pharmaceuticals: Partnering deals by technology type

Figure 55: AMAG Pharmaceuticals: Partnering deals by stage of development

Figure 56: AMAG Pharmaceuticals: Partnering deals by therapy area

Figure 57: Amgen: Dealmaking frequency 2007-2013

Figure 58: Amgen: Partnering deals by type

Figure 59: Amgen: Partnering deals by industry sector

Figure 60: Amgen: Partnering deals by technology type

Figure 61: Amgen: Partnering deals by stage of development

Figure 62: Amgen: Partnering deals by therapy area

Figure 63: Anika Therapeutics: Dealmaking frequency 2007-2013

Figure 64: Anika Therapeutics: Partnering deals by type

Figure 65: Anika Therapeutics: Partnering deals by industry sector

Figure 66: Anika Therapeutics: Partnering deals by technology type

Figure 67: Anika Therapeutics: Partnering deals by stage of development

Figure 68: Anika Therapeutics: Partnering deals by therapy area

Figure 69: Array Biopharma: Dealmaking frequency 2007-2013

Figure 70: Array Biopharma: Partnering deals by type

Figure 71: Array Biopharma: Partnering deals by industry sector

Figure 72: Array Biopharma: Partnering deals by technology type

Figure 73: Array Biopharma: Partnering deals by stage of development

Figure 74: Array Biopharma: Partnering deals by therapy area

Figure 75: Bavarian Nordic: Dealmaking frequency 2007-2013

Figure 76: Bavarian Nordic: Partnering deals by type

Figure 77: Bavarian Nordic: Partnering deals by industry sector

Figure 78: Bavarian Nordic: Partnering deals by technology type

Figure 79: Bavarian Nordic: Partnering deals by stage of development

Figure 80: Bavarian Nordic: Partnering deals by therapy area

Figure 81: Biocon: Dealmaking frequency 2007-2013

Figure 82: Biocon: Partnering deals by type

Figure 83: Biocon: Partnering deals by industry sector

Figure 84: Biocon: Partnering deals by technology type

Figure 85: Biocon: Partnering deals by stage of development

Figure 86: Biocon: Partnering deals by therapy area

Figure 87: Biogen Idec: Dealmaking frequency 2007-2013

Figure 88: Biogen Idec: Partnering deals by type

Figure 89: Biogen Idec: Partnering deals by industry sector

Figure 90: Biogen Idec: Partnering deals by technology type

Figure 91: Biogen Idec: Partnering deals by stage of development

Figure 92: Biogen Idec: Partnering deals by therapy area

Figure 93: BioMarin Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 94: BioMarin Pharmaceuticals: Partnering deals by type

Figure 95: BioMarin Pharmaceuticals: Partnering deals by industry sector

Figure 96: BioMarin Pharmaceuticals: Partnering deals by technology type

Figure 97: BioMarin Pharmaceuticals: Partnering deals by stage of development

Figure 98: BioMarin Pharmaceuticals: Partnering deals by therapy area

Figure 99: Cangene: Dealmaking frequency 2007-2013

Figure 100: Cangene: Partnering deals by type

Figure 101: Cangene: Partnering deals by industry sector

Figure 102: Cangene: Partnering deals by technology type

Figure 103: Cangene: Partnering deals by stage of development

Figure 104: Cangene: Partnering deals by therapy area

Figure 105: Celgene: Dealmaking frequency 2007-2013

Figure 106: Celgene: Partnering deals by type

Figure 107: Celgene: Partnering deals by industry sector

Figure 108: Celgene: Partnering deals by technology type

Figure 109: Celgene: Partnering deals by stage of development

Figure 110: Celgene: Partnering deals by therapy area

Figure 111: CSL: Dealmaking frequency 2007-2013

Figure 112: CSL: Partnering deals by type

Figure 113: CSL: Partnering deals by industry sector

Figure 114: CSL: Partnering deals by technology type

Figure 115: CSL: Partnering deals by stage of development

Figure 116: CSL: Partnering deals by therapy area

Figure 117: Cubist: Dealmaking frequency 2007-2013

Figure 118: Cubist: Partnering deals by type

Figure 119: Cubist: Partnering deals by industry sector

Figure 120: Cubist: Partnering deals by technology type

Figure 121: Cubist: Partnering deals by stage of development

Figure 122: Cubist: Partnering deals by therapy area

Figure 123: Dendreon: Dealmaking frequency 2007-2013

Figure 124: Dendreon: Partnering deals by type

Figure 125: Dendreon: Partnering deals by industry sector

Figure 126: Dendreon: Partnering deals by technology type

Figure 127: Dendreon: Partnering deals by stage of development

Figure 128: Dendreon: Partnering deals by therapy area

Figure 129: Elan: Dealmaking frequency 2007-2013

Figure 130: Elan: Partnering deals by type

Figure 131: Elan: Partnering deals by industry sector

Figure 132: Elan: Partnering deals by technology type

Figure 133: Elan: Partnering deals by stage of development

Figure 134: Elan: Partnering deals by therapy area

Figure 135: Emergent Biosolutions: Dealmaking frequency 2007-2013

Figure 136: Emergent Biosolutions: Partnering deals by type

Figure 137: Emergent Biosolutions: Partnering deals by industry sector

Figure 138: Emergent Biosolutions: Partnering deals by technology type

Figure 139: Emergent Biosolutions: Partnering deals by stage of development

Figure 140: Emergent Biosolutions: Partnering deals by therapy area

Figure 141: Enzo Biochem: Dealmaking frequency 2007-2013

Figure 142: Enzo Biochem: Partnering deals by type

Figure 143: Enzo Biochem: Partnering deals by industry sector

Figure 144: Enzo Biochem: Partnering deals by technology type

Figure 145: Enzo Biochem: Partnering deals by stage of development

Figure 146: Enzo Biochem: Partnering deals by therapy area

Figure 147: Galapagos: Dealmaking frequency 2007-2013

Figure 148: Galapagos: Partnering deals by type

Figure 149: Galapagos: Partnering deals by industry sector

Figure 150: Galapagos: Partnering deals by technology type

Figure 151: Galapagos: Partnering deals by stage of development

Figure 152: Galapagos: Partnering deals by therapy area

Figure 153: Genmab: Dealmaking frequency 2007-2013

Figure 154: Genmab: Partnering deals by type

Figure 155: Genmab: Partnering deals by industry sector

Figure 156: Genmab: Partnering deals by technology type

Figure 157: Genmab: Partnering deals by stage of development

Figure 158: Genmab: Partnering deals by therapy area

Figure 159: Gilead Sciences: Dealmaking frequency 2007-2013

Figure 160: Gilead Sciences: Partnering deals by type

Figure 161: Gilead Sciences: Partnering deals by industry sector

Figure 162: Gilead Sciences: Partnering deals by technology type

Figure 163: Gilead Sciences: Partnering deals by stage of development

Figure 164: Gilead Sciences: Partnering deals by therapy area

Figure 165: Grifols: Dealmaking frequency 2007-2013

Figure 166: Grifols: Partnering deals by type

Figure 167: Grifols: Partnering deals by industry sector

Figure 168: Grifols: Partnering deals by technology type

Figure 169: Grifols: Partnering deals by stage of development

Figure 170: Grifols: Partnering deals by therapy area

Figure 171: Ipsen: Dealmaking frequency 2007-2013

Figure 172: Ipsen: Partnering deals by type

Figure 173: Ipsen: Partnering deals by industry sector

Figure 174: Ipsen: Partnering deals by technology type

Figure 175: Ipsen: Partnering deals by stage of development

Figure 176: Ipsen: Partnering deals by therapy area

Figure 177: Isis Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 178: Isis Pharmaceuticals: Partnering deals by type

Figure 179: Isis Pharmaceuticals: Partnering deals by industry sector

Figure 180: Isis Pharmaceuticals: Partnering deals by technology type

Figure 181: Isis Pharmaceuticals: Partnering deals by stage of development

Figure 182: Isis Pharmaceuticals: Partnering deals by therapy area

Figure 183: LFB Group: Dealmaking frequency 2007-2013

Figure 184: LFB Group: Partnering deals by type

Figure 185: LFB Group: Partnering deals by industry sector

Figure 186: LFB Group: Partnering deals by technology type

Figure 187: LFB Group: Partnering deals by stage of development

Figure 188: LFB Group: Partnering deals by therapy area

Figure 189: Medivation: Dealmaking frequency 2007-2013

Figure 190: Medivation: Partnering deals by type

Figure 191: Medivation: Partnering deals by industry sector

Figure 192: Medivation: Partnering deals by technology type

Figure 193: Medivation: Partnering deals by stage of development

Figure 194: Medivation: Partnering deals by therapy area

Figure 195: Morphosys: Dealmaking frequency 2007-2013

Figure 196: Morphosys: Partnering deals by type

Figure 197: Morphosys: Partnering deals by industry sector

Figure 198: Morphosys: Partnering deals by technology type

Figure 199: Morphosys: Partnering deals by stage of development

Figure 200: Morphosys: Partnering deals by therapy area

Figure 201: Nektar Therapeutics: Dealmaking frequency 2007-2013

Figure 202: Nektar Therapeutics: Partnering deals by type

Figure 203: Nektar Therapeutics: Partnering deals by industry sector

Figure 204: Nektar Therapeutics: Partnering deals by technology type

Figure 205: Nektar Therapeutics: Partnering deals by stage of development

Figure 206: Nektar Therapeutics: Partnering deals by therapy area

Figure 207: Novo Nordisk: Dealmaking frequency 2007-2013

Figure 208: Novo Nordisk: Partnering deals by type

Figure 209: Novo Nordisk: Partnering deals by industry sector

Figure 210: Novo Nordisk: Partnering deals by technology type

Figure 211: Novo Nordisk: Partnering deals by stage of development

Figure 212: Novo Nordisk: Partnering deals by therapy area

Figure 213: NPS Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 214: NPS Pharmaceuticals: Partnering deals by type

Figure 215: NPS Pharmaceuticals: Partnering deals by industry sector

Figure 216: NPS Pharmaceuticals: Partnering deals by technology type

Figure 217: NPS Pharmaceuticals: Partnering deals by stage of development

Figure 218: NPS Pharmaceuticals: Partnering deals by therapy area

Figure 219: Onyx Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 220: Onyx Pharmaceuticals: Partnering deals by type

Figure 221: Onyx Pharmaceuticals: Partnering deals by industry sector

Figure 222: Onyx Pharmaceuticals: Partnering deals by technology type

Figure 223: Onyx Pharmaceuticals: Partnering deals by stage of development

Figure 224: Onyx Pharmaceuticals: Partnering deals by therapy area

Figure 225: Optimer: Dealmaking frequency 2007-2013

Figure 226: Optimer: Partnering deals by type

Figure 227: Optimer: Partnering deals by industry sector

Figure 228: Optimer: Partnering deals by technology type

Figure 229: Optimer: Partnering deals by stage of development

Figure 230: Optimer: Partnering deals by therapy area

Figure 231: PDL Biopharma: Dealmaking frequency 2007-2013

Figure 232: PDL Biopharma: Partnering deals by type

Figure 233: PDL Biopharma: Partnering deals by industry sector

Figure 234: PDL Biopharma: Partnering deals by technology type

Figure 235: PDL Biopharma: Partnering deals by stage of development

Figure 236: PDL Biopharma: Partnering deals by therapy area

Figure 237: Questcor Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 238: Questcor Pharmaceuticals: Partnering deals by type

Figure 239: Questcor Pharmaceuticals: Partnering deals by industry sector

Figure 240: Questcor Pharmaceuticals: Partnering deals by technology type

Figure 241: Questcor Pharmaceuticals: Partnering deals by stage of development

Figure 242: Questcor Pharmaceuticals: Partnering deals by therapy area

Figure 243: Regeneron Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 244: Regeneron Pharmaceuticals: Partnering deals by type

Figure 245: Regeneron Pharmaceuticals: Partnering deals by industry sector

Figure 246: Regeneron Pharmaceuticals: Partnering deals by technology type

Figure 247: Regeneron Pharmaceuticals: Partnering deals by stage of development

Figure 248: Regeneron Pharmaceuticals: Partnering deals by therapy area

Figure 249: Roche: Dealmaking frequency 2007-2013

Figure 250: Roche: Partnering deals by type

Figure 251: Roche: Partnering deals by industry sector

Figure 252: Roche: Partnering deals by technology type

Figure 253: Roche: Partnering deals by stage of development

Figure 254: Roche: Partnering deals by therapy area

Figure 255: SciClone Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 256: SciClone Pharmaceuticals: Partnering deals by type

Figure 257: SciClone Pharmaceuticals: Partnering deals by industry sector

Figure 258: SciClone Pharmaceuticals: Partnering deals by technology type

Figure 259: SciClone Pharmaceuticals: Partnering deals by stage of development

Figure 260: SciClone Pharmaceuticals: Partnering deals by therapy area

Figure 261: Seattle Genetics: Dealmaking frequency 2007-2013

Figure 262: Seattle Genetics: Partnering deals by type

Figure 263: Seattle Genetics: Partnering deals by industry sector

Figure 264: Seattle Genetics: Partnering deals by technology type

Figure 265: Seattle Genetics: Partnering deals by stage of development

Figure 266: Seattle Genetics: Partnering deals by therapy area

Figure 267: Shire: Dealmaking frequency 2007-2013

Figure 268: Shire: Partnering deals by type

Figure 269: Shire: Partnering deals by industry sector

Figure 270: Shire: Partnering deals by technology type

Figure 271: Shire: Partnering deals by stage of development

Figure 272: Shire: Partnering deals by therapy area

Figure 273: Spectrum Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 274: Spectrum Pharmaceuticals: Partnering deals by type

Figure 275: Spectrum Pharmaceuticals: Partnering deals by industry sector

Figure 276: Spectrum Pharmaceuticals: Partnering deals by technology type

Figure 277: Spectrum Pharmaceuticals: Partnering deals by stage of development

Figure 278: Spectrum Pharmaceuticals: Partnering deals by therapy area

Figure 279: Swedish Orphan Biovitrum: Dealmaking frequency 2007-2013

Figure 280: Swedish Orphan Biovitrum: Partnering deals by type

Figure 281: Swedish Orphan Biovitrum: Partnering deals by industry sector

Figure 282: Swedish Orphan Biovitrum: Partnering deals by technology type

Figure 283: Swedish Orphan Biovitrum: Partnering deals by stage of development

Figure 284: Swedish Orphan Biovitrum: Partnering deals by therapy area

Figure 285: The Medicines Company: Dealmaking frequency 2007-2013

Figure 286: The Medicines Company: Partnering deals by type

Figure 287: The Medicines Company: Partnering deals by industry sector

Figure 288: The Medicines Company: Partnering deals by technology type

Figure 289: The Medicines Company: Partnering deals by stage of development

Figure 290: The Medicines Company: Partnering deals by therapy area

Figure 291: UCB: Dealmaking frequency 2007-2013

Figure 292: UCB: Partnering deals by type

Figure 293: UCB: Partnering deals by industry sector

Figure 294: UCB: Partnering deals by technology type

Figure 295: UCB: Partnering deals by stage of development

Figure 296: UCB: Partnering deals by therapy area

Figure 297: United Therapeutics: Dealmaking frequency 2007-2013

Figure 298: United Therapeutics: Partnering deals by type

Figure 299: United Therapeutics: Partnering deals by industry sector

Figure 300: United Therapeutics: Partnering deals by technology type

Figure 301: United Therapeutics: Partnering deals by stage of development

Figure 302: United Therapeutics: Partnering deals by therapy area

Figure 303: Vertex Pharmaceuticals: Dealmaking frequency 2007-2013

Figure 304: Vertex Pharmaceuticals: Partnering deals by type

Figure 305: Vertex Pharmaceuticals: Partnering deals by industry sector

Figure 306: Vertex Pharmaceuticals: Partnering deals by technology type

Figure 307: Vertex Pharmaceuticals: Partnering deals by stage of development

Figure 308: Vertex Pharmaceuticals: Partnering deals by therapy area

Figure 309: ViroPharma: Dealmaking frequency 2007-2013

Figure 310: ViroPharma: Partnering deals by type

Figure 311: ViroPharma: Partnering deals by industry sector

Figure 312: ViroPharma: Partnering deals by technology type

Figure 313: ViroPharma: Partnering deals by stage of development

Figure 314: ViroPharma: Partnering deals by therapy area

Figure 315: Zeltia: Dealmaking frequency 2007-2013

Figure 316: Zeltia: Partnering deals by type

Figure 317: Zeltia: Partnering deals by industry sector

Figure 318: Zeltia: Partnering deals by technology type

Figure 319: Zeltia: Partnering deals by stage of development

Figure 320: Zeltia: Partnering deals by therapy area

Figure 321: Online partnering resources

Figure 322: Deal type definitions

Figure 323: Collaborative R&D and license agreement between GlaxoSmithKline and Supergen, November 2009

To order this report: Partnering Deals and Alliances with Big Biotech http://www.reportlinker.com/p01590713/Partnering-Deals-and-Alliances-with-Big-Biotech.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy


Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.